Friday, January 27, 2012

7:00 a.m. - 8:00 a.m.

Breakfast

Welcome -David Raben, MD

8:00 a.m. - 9:30 a.m.

General Session V - New Insights into Molecular Biology of SCCHN

Moderators: Christine H. Chung, MD, and Tanguy Seiwert, MD

This session will focus on the information gained from current molecular technology in the biology of head and neck cancer.

Pathway Mutations in SCCHN

Aaron Tward, MD

Molecular Profiling of Head and Neck Cancers / Head and Neck Cancer Genomics

Tanguy Seiwert, MD

Targetable Genetic Alterations in SCCHN

Christine H. Chung, MD

Targeted Agents in Phase I Head and Neck Cancer Trials

Antonio Jimeno, MD, PhD

After this session, attendees will be able to:

• Describe the implications of recent genome wide analysis of somatic mutations in head and neck squamous carcinoma.
  
• Discuss new targets that have shown promise in head and neck cancer.
  
• Report the status of clinical development of promising anticancer targets in head and neck cancer.
  
• Debate future opportunities of upcoming targets for development in head and neck cancer.

10:00 a.m. - 10:30 a.m.

General Session VI - Keynote Address II: Customizing Therapy for Patients with Local-regionally Advanced Head and Neck Carcinoma
K. Kian Ang, MD, PhD, FASTRO

This session will summarize strategies for customizing therapy for patients presenting with newly diagnosed local-regionally advanced head and neck carcinoma based on level I evidence. Data of pertinent randomized clinical trials and biomarker studies will be presented along with examples of ongoing research directions.

After this session, attendees will be able to:

• Categorize patients into proper risk-groups based on histologic and biologic prognostic markers.
• Select best treatment options based on risk features.
• Understand the rationales and objectives of ongoing research.
  

10:30 a.m. - 12:00 p.m.

Oral Abstract Session I

Moderator: Joseph Rajendran, MD

4    Evaluating the Impact of Treatement and Tumor Characteristics in the Development of Osteoradionecrosis in Patients Treated for Oral Cancers: A SEER-Medicare Analysis Beth Beadle

5     Update of RTOG 0615, A Phase II Trial of Bevacizumab, Cisplatin, and IMRT for Loco-regionally Advanced Nasopharyngeal Carcinoma

Nancy Lee

6     Pre-treatment Neurocognitive Function (NCF) Evaluation in Head and Neck Cancer (HNC) Patients (pts) with Comparison to Healthy Control Participants

Albiruni Ryan Abdul Razak

7     The Relationship Between WHO Grade, EBV and HPV Status in Nasophagyngeal Carcinoma in Non-endemic Population

Brian Khong

8     Significant Reduction in Waiting Time for Diagnosis and Treatment of Head and Neck Cancer in Denmark in 2010 Compared to 2002. First Results of the Danish National Fast Track Program for Cancer

Cai Grau

9     Differences in Billing Charges in a Matched Pair Comparison of Intensity Modulated Radiation Therapy (IMRT) versus 3-D Conformal Radiation Therapy (CRT) for the Treatment of Head and Neck Cancer

Nathan Sheets

10 Do the Quantec Criteria Defined for the Radiation Dose to the Parotid Glands Protect Against Xerostomia?

Johannes Langendijk

11 Computed Tomography as a Predictor of Actual Cartilage Invasion in Advanced Laryngeal and Hypopharyngeal Carcinoma

Michael Dominello

12 Response to Induction Chemotherapy and Dosimetric Analysis of the use of Post-Induction Chemotherapy Target Volumes in Radiotherapy for Locally Advanced Head and Neck Cancer

Jimmy Caudell

1:00 p.m. - 2:30 p.m.

General Session VII - Thyroid Cancer

Moderator: Rathan Subramaniam, MD, PhD, MPH

This session will review and update surgical management strategies for recurrent thyroid cancer, imaging and management strategies for non radio iodine avid recurrent disease and medullary thyroid cancer and genetic testing.

Surgical Management - Partial vs. Total Thyroidectomy and Recurrent Disease

Jennifer Rosen, MD

Imaging of Thyroid Cancer

Rathan Subramaniam, MD, PhD, MPH

Managment of non-RAI Avid Disease

Marcia Simpson-Brose, MD, PhD

Medullary Thyroid Cancer

Herbert Chen, MD

After this session, attendees will be able to:

• Review the indications for partial vs total thyroidectomy in upfront treatment of thyroid cancer and recurrent disease.
• Recognize the imaging and management strategies for non RAI avid disease.
  
• Describe the diagnosis and surgical management of medullary thyroid cancer (MTC) and the use of genetic testing.

2:30 p.m. - 2:45 p.m.

Break - Travel Time to Breakouts

2:45 p.m. - 3:45 p.m.

Breakout Sessions III and IV

Breakout SessionIII - Functional Outcomes and Insights into Reducing the Morbidity of Treatment

Moderator: Eric M. Genden, MD

This session will address the best approach to manage the often debilitating side effects of chemoradiotherapy. While most of the material will be derived from expert opinion, current literature has been used to formulate the approaches outlined in this session.

Breakout Session IV - Salivary Gland Cancers, Melanoma and Other Less Common Cancers of the Head and Neck

Moderator: Gerry Funk , MD

This session will review the recent advances in the areas of adenoid cystic carcinoma, melanoma and skin cancers involving the head and neck.

Prospective Mucositis Mitigation in the 21st Century - What Are We Doing to Reduce Acute Side Effects?

Adam Raben, MD

Adenoid Cystic Carcinoma: New Molecular Driven Approaches in 2012

Patrick K.Ha, MD

Cancer Cachexia in Head and Neck Cancer - How Do We Manage This Problem?

Marion Couch, MD, PhD

Surgical Head and Neck Cancer Melanoma
Michael Kupferman, MD

Prediction and Prevention of Swallowing Dysfunction After Chemoradiation

David Rosenthal, MD

Non-melanoma Skin Cancer Gerry Funk, MD

After this session, attendees will be able to:

• Describe methods to mitigate Mucositis following chemoradiotherapy.
• Define methods to manage cachexia as a result of chemoradiotherapy.
• Identify methods preventing swallowing dysfunction in patients undergoing chemoradiotherapy.
  

After this session, attendees will be able to:

• Determine molecularly targeted approaches to adenoid cystic carcinoma and understand how those may integrate into management of adenoid cystic carcinoma.
• Define the role that surgery plays in head and neck melanoma.
• Evaluate the overall approach to managing non-melanoma skin cancers including treatment modalities and predictors of outcome.
  

3:45 p.m. - 4:15 p.m.

Breakout Session V - Supportive Care During and After Treatment

Moderators: Barbara Murphy, MD, and Gerry Funk, MD

This session will review data, and increase knowledge on the interventions most effective in managing the late effects of therapy for head and neck cancer patients.

Breakout Session VI - Surgical Management of Residual/Recurrent Disease and Complications of Treatment

Moderators: Eric M. Genden, MD, and Ralph Gilbert, MD

Complications related to chemotherapy and radiotherapy can be significant and salvage surgery following the administration of these agents can be fraught with complications. This session will educate and review those techniques to limit complications and achieve a safe and effective outcome when managing the high risk patient.

Physical Therapy for Head and Neck Cancer Patients: A Critical Review of the Literature

Ann Marie Flores, PT, PhD, MS, MA

Osteoradionecrosis: Prevention and
Management

Ralph Gilbert, MD

Post-treatment Lymphedema: Incidence, Severity and Associated Symptom Burden

Jie Deng, PhD, RN, OCN

Pharyngoesophageal Stenosis: Prevention and Management

Eric M. Genden, MD

Late Oral Effects of Head and Neck Cancer Therapy

Joel Epstein, DMD, MSD

Salvage Surgery: Management and Prevention of Complications in the High-risk Patient

Theodore Teknos, MD

After this session, attendees will be able to:

• Review currently available data pertaining to the incidence, severity and impact of physical limitations on head and neck cancer patients.
• Review data and identify gaps in the physical therapy literature pertaining to head and neck cancer patients.
• Discuss the prevalence, severity and associated sequellea of lymphedema in the head and neck population.
• Describe the incidence, severity and implications of late oral complications in the head and neck population.
  

• Evaluate techniques for prevention of complications related osteoradionecrosis.
• Describe the approach to management of esophageal stenosis following chemoradiotherapy.
• Determine patient populations that are at risk for wound break down following salvage surgery.
  

Case-based Discussions II - Moderator:  Merril S. Kies, MD

Discussants - David M. Brizel, MD, FASTRO, Marshall Posner, MD, and Randal S. Weber, MD

Welcome - Randal Weber, MD

8:00 a.m. - 9:30 a.m.

General Session VIII - New Issues and Concepts in Radiotherapy for Head and Neck Cancer

Moderator: Louis B. Harrison, MD

This session will introduce innovative and personalized multidisciplinary management for patients with recurrent head and neck cancer.

Evolving Concepts in the Management of the Neck

Brian O'Sullivan, MD, FASTRO

Can We Spare the Opposite Submandibular Gland in Head and Neck Cancer Radiotherapy and is it Safe?

William Mendenhall, MD

The Implications of Tumor Volume on Treatment Decisions and Functional Outcomes for Patients With Locally Advanced Head and Neck Cancers

Mohan Suntha, MD

New Approaches to Salvage Therapy

Louis B. Harrsion, MD, FASTRO

Stereotacic Radioablation - How do we Incorporate This into Management?

David Raben, MD

• Discuss contemporary approaches to multi-modality therapy with surgery, radiation therapy and chemotherapy for locoregional recurrence of squamous cell cancer of the head and neck.
• Identify evolving concepts in multimodality decision-making for squamous cell carcinoma of the head and neck to realize optimal control while minimizing morbidity for the elective(N0) and involved (N+) neck.
• Recognize the impact of tumor volume on treatment decisions and outcome for patients with locally advanced squamous cell carcinomas of the head and neck.
• Define the role of submandibular gland sparing IMRT in the treatment of head and neck cancer

10:00 a.m. - 11:30 a.m.

General Session IX - Human Papillomavirus Issues and Controversies in 2012

Moderators: Maura Gillison, MD, PhD, and Danny Rischin, MD, MBBS

This session will focus on the need to disseminate additional clinical expertise in the diagnostic and therapeutic implications of HPV-related disease.

HPV Positive Disease - Clinical Trial Design

Maura Gillison, MD, PhD

HPV Testing - What is the Optimal Algorithm to be Sure?

Tom Carey, PhD

Cellular Immunity and HPV: Should Patients Get Vaccinated? Sara Pai, MD, PhD

Investigational Therapy in HPV Negative Head and Neck Cancer Barbara Burtness, MD

• Discuss the prognostic impact of tumor HPV status.
• Develop appropriate interpretation of HPV testing results.
• Differentiate between preventative versus therapeutic HPV vaccines.
• Describe novel approaches to HPV-negative cancers.